according to GB/T 16483 and GB/T 17519



# **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 2025/04/14 6097530-00017 Date of first issue: 2020/06/30 7.0

#### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ivermectin Formulation

Manufacturer or supplier's details

Company : MSD

Address No. 485 Jing Tai Road

Pu Tuo District - Shanghai - China 200331

Telephone +1-908-740-4000

Emergency telephone number: 86-571-87268110

E-mail address EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use Veterinary product Not applicable Restrictions on use

#### 2. HAZARDS IDENTIFICATION

## **Emergency Overview**

**Appearance** oily

Colour light yellow Odour characteristic

May be harmful if swallowed. May cause damage to organs. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

### **GHS Classification**

Acute toxicity (Oral) : Category 5

Specific target organ toxicity - : Category 2

single exposure

Specific target organ toxicity - :

Category 2

repeated exposure

Short-term (acute) aquatic

Category 1

hazard

Long-term (chronic) aquatic : Category 1

hazard

according to GB/T 16483 and GB/T 17519



## **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

#### **GHS** label elements

Hazard pictograms





Signal word : Warning

Hazard statements : H303 May be harmful if swallowed.

H371 May cause damage to organs.

H373 May cause damage to organs through prolonged or re-

peated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P260 Do not breathe mist or vapours. P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

Response:

P301 + P317 IF SWALLOWED: Get medical help.

P308 + P316 IF exposed or concerned: Get emergency medi-

cal help immediately. P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

#### Physical and chemical hazards

Not classified based on available information.

### **Health hazards**

May be harmful if swallowed. May cause damage to organs. May cause damage to organs through prolonged or repeated exposure.

#### **Environmental hazards**

Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

# Other hazards which do not result in classification

None known.

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name CAS-No. Concentration (% w/w)

according to GB/T 16483 and GB/T 17519



# Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

Ivermectin	70288-86-7	>= 1 -< 2.5
2,6-Di-tert-butyl-p-cresol	128-37-0	>= 0.25 -< 1

4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

Wash with water and soap as a precaution. In case of skin contact

Get medical attention if symptoms occur.

Flush eyes with water as a precaution. In case of eye contact

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting unless directed to do

> so by medical personnel. Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and

May be harmful if swallowed. May cause damage to organs.

delayed

May cause damage to organs through prolonged or repeated

exposure.

First Aid responders should pay attention to self-protection, Protection of first-aiders

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

5. FIREFIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

according to GB/T 16483 and GB/T 17519



# **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

## 7. HANDLING AND STORAGE

## Handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

according to GB/T 16483 and GB/T 17519



## **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

Avoidance of contact : Oxidizing agents

**Storage** 

Conditions for safe storage : Keep in properly labelled containers.

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

#### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of	Control parameters / Permissible	Basis	
		exposure)	concentration		
Ivermectin	70288-86-7	TWA	30 μg/m3 (OEB 3)	Internal	
	Further information: Skin				
		Wipe limit	300 μg/100 cm2	Internal	
2,6-Di-tert-butyl-p-cresol	128-37-0	TWA (Inhalable fraction and vapor)	2 mg/m3	ACGIH	

**Engineering measures** : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

tainment devices). Minimize open handling.

## Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

according to GB/T 16483 and GB/T 17519



## **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : oily

Colour : light yellow

Odour : characteristic

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

167.5 °C

Flash point : 219.2 °C

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

according to GB/T 16483 and GB/T 17519



# **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

Relative vapour density : No data available

Relative density : 0.88 - 0.92

Density : No data available

Solubility(ies)

Water solubility : practically insoluble

Partition coefficient: n-

octanol/water

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

# 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- :

tions

Can react with strong oxidizing agents.

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardou

products

: No hazardous decomposition products are known.

## 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

**Acute toxicity** 

May be harmful if swallowed.

according to GB/T 16483 and GB/T 17519



# **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

**Product:** 

Acute oral toxicity : Acute toxicity estimate: 5,000 mg/kg

Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

**Components:** 

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg

LD50 (Mouse): 25 mg/kg

LD50 (Monkey): > 24 mg/kg

Target Organs: Central nervous system Symptoms: Vomiting, Dilatation of the pupil Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l

Exposure time: 1 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg

LD50 (Rat): > 660 mg/kg

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg

Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Ivermectin:

Species : Rabbit

Result : No skin irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

according to GB/T 16483 and GB/T 17519



# **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

Remarks : Based on data from similar materials

## Serious eye damage/eye irritation

Not classified based on available information.

#### **Components:**

#### Ivermectin:

Species : Rabbit

Result : Mild eye irritation

### 2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Remarks : Based on data from similar materials

## Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### **Components:**

#### Ivermectin:

Exposure routes : Dermal Species : Humans

Result : Does not cause skin sensitisation.

## 2,6-Di-tert-butyl-p-cresol:

Test Type : Human repeat insult patch test (HRIPT)

Exposure routes : Skin contact
Species : Humans
Result : negative

## Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

### Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

according to GB/T 16483 and GB/T 17519



# **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

Test system: human diploid fibroblasts

Result: negative

Test Type: Mouse Lymphoma

Result: negative

2,6-Di-tert-butyl-p-cresol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

## Carcinogenicity

Not classified based on available information.

# **Components:**

#### Ivermectin:

Species : Rat Application Route : Oral

NOAEL : 1.5 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

Species : Mouse Application Route : Oral

NOAEL : 2.0 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

## 2,6-Di-tert-butyl-p-cresol:

Species : Rat
Application Route : Ingestion
Exposure time : 22 Months
Result : negative

#### Reproductive toxicity

Not classified based on available information.

according to GB/T 16483 and GB/T 17519



# **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

#### **Components:**

#### Ivermectin:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 0.6 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Development

Species: Mouse

Application Route: Oral

Developmental Toxicity: NOAEL: 0.2 mg/kg body weight Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 0.4 mg/kg body weight Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Remarks: The mechanism or mode of action may not be rele-

vant in humans.

Test Type: Development

Species: Rabbit Application Route: Oral

Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

## 2,6-Di-tert-butyl-p-cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

**Application Route: Ingestion** 

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

## STOT - single exposure

May cause damage to organs.

according to GB/T 16483 and GB/T 17519



# **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 2025/04/14 6097530-00017 7.0 Date of first issue: 2020/06/30

#### **Components:**

#### Ivermectin:

Target Organs Central nervous system Assessment Causes damage to organs.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### Components:

### Ivermectin:

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

## 2,6-Di-tert-butyl-p-cresol:

No significant health effects observed in animals at concentra-Assessment

tions of 100 mg/kg bw or less.

## Repeated dose toxicity

## **Components:**

#### Ivermectin:

Species Dog NOAEL : 0.5 mg/kg LOAEL
Application Route
Exposure time
Target Organs : 1 mg/kg : Oral : 14 Weeks

: Central nervous system

Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species Monkey NOAEL : 1.2 mg/kg Application Route Oral Exposure time : 2 Weeks

Remarks : No significant adverse effects were reported

Species Rat NOAEL 0.4 mg/kg LOAEL 0.8 mg/kg Application Route Oral Exposure time 3 Months

Target Organs spleen, Bone marrow, Kidney

#### 2,6-Di-tert-butyl-p-cresol:

**Species** Rat NOAEL 25 mg/kg

according to GB/T 16483 and GB/T 17519



# **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

Application Route : Ingestion Exposure time 22 Months

## **Aspiration toxicity**

Not classified based on available information.

#### **Experience with human exposure**

## **Components:**

## Ivermectin:

Skin contact Remarks: Can be absorbed through skin.

Eye contact Remarks: May irritate eyes.

Ingestion Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vom-

iting, anorexia, Lack of coordination

## 12. ECOLOGICAL INFORMATION

## **Ecotoxicity**

#### Components:

## Ivermectin:

Toxicity to fish LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l

Exposure time: 96 h

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- :

10,000

M-Factor (Chronic aquatic

10,000

toxicity)

## 2,6-Di-tert-butyl-p-cresol:

Toxicity to fish LC50 (Danio rerio (zebra fish)): > 0.57 mg/l

Exposure time: 96 h

Method: Directive 67/548/EEC, Annex V, C.1.

according to GB/T 16483 and GB/T 17519



# Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 6097530-00017 7.0 2025/04/14 Date of first issue: 2020/06/30

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 0.48 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-: 1

Toxicity to fish (Chronic tox-

icity)

NOEC (Oryzias latipes (Japanese medaka)): 0.053 mg/l

Exposure time: 30 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other: aquatic invertebrates (Chron-

ic toxicity)

M-Factor (Chronic aquatic

toxicity)

Toxicity to microorganisms

Exposure time: 21 d

NOEC (Daphnia magna (Water flea)): 0.316 mg/l

EC50: > 10,000 mg/l Exposure time: 3 h

Method: OECD Test Guideline 209

## Persistence and degradability

# **Components:**

Ivermectin:

Biodegradability Result: Not readily biodegradable.

: 1

Biodegradation: 50 % Exposure time: 240 d

2,6-Di-tert-butyl-p-cresol:

Biodegradability Result: Not readily biodegradable.

> Biodegradation: 4.5 % Exposure time: 28 d

Method: OECD Test Guideline 301C

## **Bioaccumulative potential**

### **Components:**

Ivermectin:

according to GB/T 16483 and GB/T 17519



## **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-

octanol/water

: log Pow: 3.22

2,6-Di-tert-butyl-p-cresol:

Bioaccumulation : Species: Cyprinus carpio (Carp)

Bioconcentration factor (BCF): 330 - 1,800

Partition coefficient: n-

octanol/water

log Pow: 5.1

Mobility in soil

No data available

Other adverse effects

No data available

### 13. DISPOSAL CONSIDERATIONS

**Disposal methods** 

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

## 14. TRANSPORT INFORMATION

## **International Regulations**

**UNRTDG** 

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo

aircraft)

: 964

Packing instruction (passen-

ger aircraft)

964

according to GB/T 16483 and GB/T 17519



## **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

Environmentally hazardous : yes

**IMDG-Code** 

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### **National Regulations**

GB 6944/12268

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

Class : 9
Packing group : III
Labels : 9
Marine pollutant : no

## Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## 15. REGULATORY INFORMATION

## National regulatory information

### Law on the Prevention and Control of Occupational Diseases

### **Regulations on Safety Management of Hazardous Chemicals**

Catalogue of Hazardous Chemicals : This product is not listed in the cata-

logue of hazardous chemicals, but it meets the definition of hazardous chemicals and its principles of de-

termination.

Identification of Major Hazard Installations for Hazardous Chemicals (GB : Not listed

18218)

Hazardous Chemicals for Priority Management under : Not listed

SAWS

Catalogue of Specially Controlled Hazardous Chemi: Not listed

according to GB/T 16483 and GB/T 17519



## Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

cals

List of Explosive Precursors : Not listed

Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import : Not listed

and Export

**Regulation on the Administration of Precursor Chemicals** 

Catalogue and Classification of Precursor Chemicals : Not listed

**Yangtze River Protection Law** 

This product does not contain any dangerous chemicals prohibited for inland river transport.

Regulations of Ozone Depleting Substances Management

List of Controlled Ozone Depleting Substances Import : Not listed

and Export

List of Controlled Ozone Depleting Substances Not listed

**Environmental Protection Law** 

List of Priority Controlled Chemicals Not listed

ist of Key Controlled New Pollutants Not listed

The components of this product are reported in the following inventories:

**AICS** : not determined

DSL not determined

**IECSC** not determined

**16. OTHER INFORMATION** 

**Revision Date** : 2025/04/14

**Further information** 

Sources of key data used to :

compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

according to GB/T 16483 and GB/T 17519



# **Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/09/28 7.0 2025/04/14 6097530-00017 Date of first issue: 2020/06/30

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk, IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

#### **Disclaimer**

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN